Compare FTFT & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTFT | ACET |
|---|---|---|
| Founded | N/A | 1947 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.0M | 28.0M |
| IPO Year | 2008 | 2017 |
| Metric | FTFT | ACET |
|---|---|---|
| Price | $3.65 | $3.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $29.00 |
| AVG Volume (30 Days) | ★ 912.7K | 209.7K |
| Earning Date | 11-24-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,829,805.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 77.46 | N/A |
| 52 Week Low | $0.55 | $0.46 |
| 52 Week High | $90.87 | $9.97 |
| Indicator | FTFT | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 56.28 | 21.44 |
| Support Level | $3.04 | N/A |
| Resistance Level | $3.64 | $9.51 |
| Average True Range (ATR) | 0.58 | 0.26 |
| MACD | 0.13 | 0.08 |
| Stochastic Oscillator | 80.48 | 13.64 |
Future FinTech Group Inc is engaged in the production and sale of fruit juice concentrates (including fruit purees and fruit juices), fruit beverages (including fruit juice beverages and fruit cider beverages) in the PRC. The company participates in supply chain financing services and trading in China, asset management business in Hong Kong, and cross-border money transfer services in the United Kingdom. It has also expanded into brokerage and investment banking business in Hong Kong and a cryptocurrency mining farm in the U.S. The Company classified its business segments into Trading Commission and Consulting services, Fast-Moving Consumer Goods (FMCG), and Supply Chain Financing and Trading.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).